
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is for people who have an advanced solid tumour (particularly lung cancer).
It is for people who have 1 of the following:
A solid tumour is any type of cancer apart from leukaemia or lymphoma.
An advanced solid tumour is a cancer that has grown into surrounding tissues (locally advanced) or spread elsewhere in the body (advanced).
Researchers are looking at ways to improve treatment for people with advanced solid tumours. In this study, they are looking at a new drug called OMO-1. It is a type of targeted drug. OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase. This means it stops signals that cancer cells use to divide and grow.
We know from research that some cancer cells have a large number of copies of a gene called MET. Or they have a change (mutation) in the MET gene.
Researchers think that OMO-1 will work better in people with a MET gene change or in people who have too many copies of this gene. Blocking the MET gene might stop the growth of cancer cells.
This is the first time people with cancer are having OMO-1.
The aims of the study are to:
The following bullet points list the main entry conditions for this study. Talk to your doctor or the study if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this study if all of the following apply.
You:
As well as the above, the following must also apply for some people who join:
Who can’t take part
You cannot join this study if any of these apply.
Cancer related
You can’t take part if you:
Medical conditions
You can’t take part if you:
Other
You can’t take part if you:
This is a phase 1/2 study. The researchers need people 80 people to take part including as many as possible from the UK.
There are 2 parts to this trial. Part A and Part B. In Part A, the researchers are looking at the best dose of OMO-1. This part is now complete.
In Part B they will find out more about how well treatment works. Part B is open for people to join.
Part B
OMO-1 is a capsule. You take it twice a day, everyday. You have treatment in cycles. Each 3 week period is a cycle of treatment.
You have treatment for as long as it is working, and the side effects aren’t too bad. You stop treatment if the cancer gets worse.
Samples for research
The study team might ask you to give:
They plan to use the samples to look at your genetic material (DNA), in your blood and tissue cells. Knowing more about people’s genetic material might help the doctors to understand more about cancer and how treatment works.
Depending on when you join the study, you don’t have to give these samples if you don’t want to. You can still take part in the study.
You’ll see a doctor and have some tests before you can take part. These include:
You might also have an eye test.
The first day of each treatment cycle is called day 1. In the first treatment cycle you go to hospital on:
After that, you go to hospital on day 1 of each treatment cycle.
At each visit you:
You have a CT scan or MRI scan every 6 weeks.
Follow up
When you finish treatment you go back to hospital 1 month later for a check up.
As OMO-1 is a new drug, there may be some side effects we don’t know about yet. The study team will monitor you during the time you have treatment and you’ll have a phone number to call if you are worried about anything.
A few people have had OMO-1 so far. The possible side effects of OMO 1 include:
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Martjin Paul Lolkema
OCTIMET Oncology NV
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”